Psilocybin: promising results in double-blind trials require confirmation by real-world evidence

Affiliations

¹ Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands D.E.Grobbee@umcutrecht.nl.

Comment

Alasdair Breckenridge et al. J Psychopharmacol. 2016 Dec.

. 2016 Dec;30(12):1218-1219.

doi: 10.1177/0269881116675784.

¹ Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands D.E.Grobbee@umcutrecht.nl.

No abstract available

Comment on

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Ross S, et al. J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512. J Psychopharmacol. 2016. PMID: 27909164 Free PMC article. Clinical Trial.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. J Psychopharmacol. 2016. PMID: 27909165 Free PMC article. Clinical Trial.